Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 9/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10482437 | 0.80 | HSD17B10 (0.43) | FKBP1ASMN1; SMN2AVPR2HSD17B10POLB | |
| SCHEMBL10482440 | 0.80 | HSD17B10 (0.43) | FKBP1ASMN1; SMN2AVPR2HSD17B10POLB | |
| SCHEMBL6407009 | 0.79 | ACE (0.60) | ACEHSD17B10CYP2C19LMNAKMT2A | |
| SCHEMBL11932167 | 0.79 | HSD17B10 (0.50) | FKBP1ASMN1; SMN2HSD17B10POLBKLK5 | |
| SCHEMBL750515 | 0.79 | HSD17B10 (0.50) | FKBP1ASMN1; SMN2HSD17B10POLBKLK5 | |
| SCHEMBL3591879 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2HSD17B10POLBLMNAALDH1A1 | |
| SCHEMBL4473488 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2HSD17B10POLBLMNAALDH1A1 | |
| SCHEMBL11032344 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2HSD17B10POLBLMNAALDH1A1 | |
| SCHEMBL7286305 | 0.76 | HSD17B10 (0.61) | SMN1; SMN2HSD17B10POLBLMNAALDH1A1 | |
| SCHEMBL7886209 | 0.76 | HSD17B10 (0.47) | FKBP1ASMN1; SMN2HSD17B10POLBKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852752-B2 | Urea compounds, compositions and methods of use and preparation | VICURON PHARMACEUTICALS INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20020119962-A1 | Novel urea compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-29 | — | — | US | disclosed |
| WO-2001044178-A1 | NOVEL UREA COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119962-A1 | Novel urea compounds, compositions and methods of use and preparation | PDF, UROD, HDHD5 | FKBP1A 3159/4885ACE 1344/4885SMN1; SMN2 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.